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OBJECTIVES: To compare cost-effectiveness of rosuvastatin (RSV) versus
ezetimibe/simvastatin (E/S) in achieving LDL-C goals (NCEP-ATP III 2001 and 2004
guidelines), in daily outpatient practice in Mexico.METHODS: Retrospective study.
From January 2004 to December 2010, outpatient medical records in 15 Mexican
hospitals/clinics were reviewed to identify patients with dyslipidemia and their
corresponding serum lipidmeasurements documented before receiving drug ther-
apy with either RSV (5mg, 10mg, or 20mg once daily) or E/S (5/5mg, 10/10mg, 10/
20mg or 10/40mg once daily); and lipid levels recorded at least after 8 weeks of
treatment. The efficacywas assessed by a) the proportion of patients who achieved
the LDL-C goal, and b) the percent reduction in LDL-C after 8 weeks of treatment. A
cost-effectiveness analysis was performed from an institutional perspective, using
the exchange rate of August 2011 of 12.2424 pesos/USD. RESULTS: Using ATP III
2001 criteria, percentage of patients who reached LDL-C goals was RSV: 81.3% and
E/S 77.1% (p  0.2972). Using ATP III 2004 criteria were: RSV, 61.3% vs. E/S, 58.5%
(p0.2548). The average treatment cost was statistically significant higher for E/S
patients (239.49 USD) versus 192.74 USD for RSV patients (p0.0033). The cost of 1%
reduction in LDL-Cwas RSV: 4.69 USD and E/S: 7.13 USD. Cost per patient treated to
ATP-III goal 2001 criteria was: RSV, 219.5 USD versus E/S, 306.0 USD and treated to
ATP-III goal 2004 criteria was: RSV, 282.2 versus E/S, 459.1 USD. The overall inci-
dence rate of adverse events was E/S: 19.5% versus RSV: 15.3%. The percentage of
patients reporting moderate or severe adverse events was E/S: 6.8% and RSV: 4.7%.
CONCLUSIONS: According to this exploratory, non-controlled retrospective study,
in daily clinical practice in Mexican dyslipidemic patients, treatment with RSV has
similar efficacy and safety, but it is more cost-effectiveness than E/S in reaching
cholesterol goals.
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OBJECTIVES: To compare costs and effectiveness of dabigatran etexilate (DAB)
versus warfarin (WAR) in patients with Non-Valvular Atrial Fibrillation (NVAF)
from a private and public health care system perspective in Brazil. METHODS: A
Markov model was built to compare DAB versus WAR to derive the incremental
cost effectiveness ratio (ICER) of DAB, based on the international literature and a
modified Delphi panel with Brazilian experts (local clinical practice pattern on the
management of NVAF patients). The model estimated the number of ischaemic
and haemorrhagic strokes, systemic embolisms, intracranial hemorrhages, tran-
sient ischaemic attacks, extracranial hemorrhages, minor bleeds and acute myo-
cardial infarctions associated with the respective treatments. To each clinical
event costs, disabilities and/or reduction in quality of life, and risk of death were
assigned. Only direct medical costs were considered and a discount rate of 5% was
assumed, according to BrazilianHTA guidelines. A probabilistic sensitivity analysis
was designed to assess uncertainty. RESULTS: Under both, the private and public
perspective, DAB was associated with additional 0.30 life years gained (LY), addi-
tional 0.35 QALYs and demonstrated a lower incidence of intracranial events ver-
sus WAR, resulting in lower event costs and follow-up costs. The ICER for DAB
versus WAR was R$ 39,740/LY and R$ 34,867/QALY from the public and R$
25,252.48/LY and R$ 22,160.20/QALY from the private perspective. Sensitivity anal-
yses confirmed the cost-effectiveness of DAB. CONCLUSIONS: Findings suggest
that DAB can be cost-effective for stroke prevention when used instead of WAR in
NVAF patients in Brazil, given that the ICERS were below the threshold of other
technologies reimbursed.
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OBJECTIVES: To assess the cost-effectiveness of the novel fixed-dose anticogulant,
rivaroxaban, in comparisson to the current dose-volatile standard of care, warfa-
rin, for the prevention of stroke in high-risk atrial fibrillation patients.METHODS:
AMarkovmodel was constructed tomodel the costs and health outcomes of treat-
ments, potential adverse events, and resulting health states over 35 years. Analy-
ses were based on a hypothetical cohort of 65 year-old patients with chronic atrial
fibrillation and high risk of stroke. The main outcome measure was cost per qual-
ity-adjusted-life-years (QALYs) gained over the lifetime andwas assessed from the
UK’s National Health Service (NHS) perspective. Costs and utility data were drawn
from previously published and publically available data, while event probabilities
were adopted from both the literature and limited data from rivoroxaban’s phase
III trial. RESULTS: Stroke prophylaxis with rivaroxaban offers lifetime health im-
provements over warfarin treatment, yet at substantial cost. From the NHS’ per-
spective, rivaroxaban’s baseline cost of £38,121 per QALY exceeds the typical will-
ingness to pay threshold. Nonetheless, the results were sensitive to adjustments of
several key variables,most notably the price of rivaroxaban, utility of warfarin, risk
of bleeding-related eventswithwarfarin, anddiscount rate for outcomes, justifying
further consideration by NICE and the NHS. CONCLUSIONS: Novel anticoagulants
such as rivaroxaban are one of many strategies being considered to replace stan-
dard warfarin therapy andmitigate its compounding weaknesses of frequent dose
regulation and bleeding risk. Our results, though far from offering backbone for the
substitution of rivaroxaban for warfarin treatment across the NHS, justify atten-
tion to this and other fixed-dose therapies as a potential alternative to warfarin-
based stroke prevention strategies. In addition tomore detailed subgroup analysis,
further research ought to consider evaluating patient, caregiver, and indirect costs,
long-term impacts on health-system demand, and comparing novel anticoagula-
tion therapies against each other.
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OBJECTIVES: To estimate the cost-effectiveness of dronedarone in Turkey com-
pared to standard of care (SOC), amiodarone and sotalol as the cost per life-year
gained (LYG). METHODS: Cost-effectiveness of dronedarone compared to SOC,
amiodarone and sotalol was estimated in a health economic microsimulation
model with transition probabilities based on ATHENA trial and relative risks of
events for amiodarone and sotalol are taken from mixed treatment comparison
(MTC) based on a systematic review of the clinical trials of AF. There were 7 health
states; on anti-arrhythmic drug (AAD), off AAD, stroke, post-stroke, chronic heart
failure, post chronic heart failure, acute coronary syndrome, symptomatic AF and
death. Each simulation included 1,000,000 patients; in all simulations patients
were followed for life or end of simulation (max 28 years). Risk of having an adverse
event (AE) for patients on dronedarone compared to SOC was from ATHENA trial
and compared to amiodarone from theDIONYSOS trial. Costswere valued from the
Social Security Institution perspective using official price lists and App2/D dis-
counts. A Delphi survey was conducted with 8 specialists to estimate treatment
and hospitalization costs. RESULTS: Non-permanent AF patients taking droneda-
rone on top of SOC lived on average 0.14 years longer compared with SOC alone.
The incremental cost-effectiveness ratio (ICER) was estimated as 11,400TL/LYG.
When comparing dronedarone with amiodarone and sotalol, patients on droneda-
rone lived 1.17 years and 2.28 years longer respectively. The ICERs for dronedarone
compared to amiodarone and sotalol were estimated as 4,300TL/LYG and 3,100TL/
LYG, respectively. CONCLUSIONS: It is difficult for the results of the analysis to be
interpreted because there is no official cost-effectiveness threshold in Turkey.
From the WHO perspective, however, results showed that dronaderone is a highly
cost-effective treatment with all ICER values compared to SOC, amiodarone and
sotalol below 3 X GDP per capita; 70,857TL (3 X 23,619TL).
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OBJECTIVES: As far as combination of aspirin and clopidogrel was recently recom-
mended by Russian National Society of Cardiology as well as AHA “when oral
anticoagulation with warfarin is considered unsuitable”, the urgent need to com-
pare its cost-effeciveness with novel oral anticoagulant dabigatran is appear.
METHODS: Present study was based on Markov model with 10 years time horizon
simulated the cohort of 10 000 AF patients at moderate-to-high stroke risk while
tracking clinical events and resulting functional disability. Direct expenses associ-
ated with complications and resulting long-term follow-up costs were calculated
using general tariff agreement of Russian obligatory insurance system and official
national statistics. RE-LY, ActiveW trials and publishedmetaanalises were used as
main clinical data sources. Clinical events per 100 patient-years, total costs and
incremental cost effectiveness ratio (ICER) for both therapy regimens were evalu-
ated. The robustness and stability of the results were tested using sensitivity and
PSA analyses. RESULTS: Over a 10 years period patients treated with dabigatran in
comparison with those receiving dual antiplatelet therapy experienced fever isch-
emic strokes (1.8 vs. 3.49), extracranial bleedings (2.53 vs. 2.76) and hemorrhagic
strokes (0.41 vs. 0.44) per 100 patient-years. Total cost ofmedications accounted for
266,089 Roubles in dabigatran group and 249,870 Roubles in dual antiplatelet ther-
apy group, cost of complications treatment – 12,500 Roubles and 18,182 Roubles,
cost of follow-up after occurred complications and rehabilitation – 24987 Roubles
and 37620 Roubles per 100 patients respectively. In total, absolute cost-saving as-
sociated with dabigatran use was 20,948 Roubles per 100 patients. CONCLUSIONS:
Dabigatran use in stroke prevention in atrial fibrillation may be considered as
cost-saving alternative to aspirin plus clopidogrel combination in patients with
warfarin intolerance.
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OBJECTIVES: The reported impact of post-discharge therapeutic educational inter-
ventions (TEIs) in patients with cardiovascular diseases is controversial and has
been poorly addressed in cost-utility studies.We developed amodeling framework
for studying the cost-utility of TEIs in this setting. METHODS: We modeled the
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impact of TEIs in patients after an acute coronary syndrome (ACS patients) and in
patients with chronic heart failure (CHF patients). We developed multi-state
Markov cycle decision trees where TEIs were compared with no intervention.
Model parameters and outcomes were extracted from a reanalysis of a recent
randomized trial in ACS patients, and from a literature search in CHF patients. For
both models, the study was conducted adopting the health care payer perspective
and time horizon was one year. TEI incremental cost-utility ratios (ICURs) were
expressed in 2011 €/QALY and US $/QALY for ACS and CHF patients, respectively.
Base cases analyses were completed by univariate and probabilistic sensitivity
analyses. RESULTS: TEI was more expensive and less effective than no interven-
tion considering the whole ACS patients population. In the subgroup of ACS pa-
tients with one risk factor and no previous history of ACS, however, the ICUR was
20,343 €/QALY. In this subgroup, the probabilistic sensitivity analysis also indicated
that TEI was not cost-effective in a substantial number of simulated iterations. TEI
was dominant–i.e. less expensive and more effective than no intervention–in the
base-case analysis of CHF patients, with 5448 $ saved per QALY. In the sensitivity
analyses, TEI cost-utility was confirmed in most cases and the cost of readmission
was the most sensitive parameter. CONCLUSIONS: Results illustrate the helpful-
ness of cost-utility modeling for identifying subgroups of patients who should be
targeted by TEIs and which measurements require particular attention in cost-
utility evaluation. Our modeling framework could be helpful for evaluating the
cost-utility of TEIs in other settings.
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OBJECTIVES: The objective of this study was to evaluate the cost-effectiveness of
drugs from 4 classes of antihypertensive medications for use in management of
hypertension in Nigerians without compelling indication to use a particular anti-
hypertensive drug. METHODS: The study employed decision analytic modeling.
Interventions were obtained from a meta-analysis. The Markov process model
calculated clinical outcomes and costs during a life cycle of 30 years of 1000 hyper-
tensive patients stratified by 3 cardiovascular risk groups, under the alternative
intervention scenarios. Quality adjusted life year (QALY) was used to quantify clin-
ical outcome. The average cost of treatment for the 1000 patient was tracked over
theMarkov cyclemodel of the alternative interventions and resultswere presented
in 2010 US Dollars. Probabilistic cost-effectiveness analysis was performed using
Monte Carlo simulation, and results presented as cost-effectiveness acceptability
frontiers. Expected value of perfect information (EVPI) and expected value of pa-
rameter perfect information (EVPPI) analyses were also conducted for the hypo-
thetical population. RESULTS: Thiazide diuretic was themost cost-effective option
across the three cardiovascular risk groups. Calcium channel blocker was the sec-
ond best for Moderate risk and high risk with a willingness to pay of at least
2000$/QALY. The result was robust since it was insensitive to the parameters
alteration. CONCLUSIONS: The result of this study showed that thiazide diuretic
followed by calcium channel blocker could be a feasible strategy in order to ensure
that patients with hypertension are better controlled.
PCV62
UTILISATION OF DRUGS INVOLVED IN TREATMENT OF CARDIOVASCULAR
DISEASES IN SLOVAK REPUBLIC WITHIN THE YEARS 2008– 2011
Bellova K1, Gatialova K2, Foltan V2, Majtas J2
1Comenius University, Bratislava, Slovak Republic, 2Pharmaceutical faculty Comenius University,
Bratislava, Slovak Republic
OBJECTIVES: The evaluation of the utilisation of drugs involved in treatment of
CVD, its consumption in terms of expenditures units and number of packages
prescribedwithin 2008 -2011.METHODS:Analysed datawere abstracted fromState
Institute for Drug Control SR and studied in accordance with financial units (€) and
number of packages prescribed every year. RESULTS: The overall consumption of
drugs involved in tretament of CVD in number of packages prescribedwas increas-
ing from 2008 until 2010. In 2011 very slight decrease can be seen (3,8% from 37 331
100 to 35 913 249). In terms of financial units, the consumption of drugs increased
from 181 319 656,40€ in 2008 to 194 185 283,80€ in 2011(the highest). The most
prescribed ATC group was C09- Renin –Angiotensin System agents (24%, with its
peak in 2010 - 9076 419 packages), in financial view it represents 33% (246 521 428,70
€) of all expeditures on CVD drugs (749 777 407,30 €) . Out of this group, C09A – ACEI
plain was the onemost prescribed with its peak in 2008 (4 820 987 packages, 23 172
192,40€), eventhough its prescription has decreasing tendency (the lowest in 2011
only 4 064 845, 17 262 264,40€). CONCLUSIONS: Obtained data proved that despite
slight decrease in the number of prescribed drugs in 2011, the financial expendi-
tures for cardiovascular medicines increase every year. The most prescribed were
C09 the Renin- Angiotensin System agents – C09AACEI plain, but the expenses had
a decreasing tendency. According to this study, there is no continual proportion
between amount of prescribed medicine and the amount of expenses on CVD.
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OBJECTIVES: It is estimated that over 100 million Americans currently have high
blood pressure, high cholesterol or both, and most of these individuals do not
properly control their conditions. This study assesses the relationships between
employee adherence to both statins and antihypertensives and the short-term
disability costs in a large manufacturing company. METHODS: A retrospective
analysis of pharmacy claims was conducted to identify individuals within a large
manufacturing company who were continuously eligible for a three-year time
frame (between 2001 and 2007) and who received a prescription for both an anti-
hypertensive and a statin during that time. In those cases where an individual’s
eligibility spanned a longer time period, the most recent three-year span was cho-
sen. The resulting sample included both treatment-naïve and treatment-experi-
enced patients.Medical, pharmacy, and short-termdisability costswere calculated
for a one year follow-up. Adherence was measured using proportion of days cov-
ered (PDC), where a PDC80was considered adherent. Multi-variable linear regres-
sion was used to examine the relationships between cost and adherence, control-
ling for patient demographics (age, gender, and job type) and Charlson co-
morbidity score. RESULTS: Among the 10575 individuals in the study, the mean
adherence to these cardiovascular medication classes was 67%, and 46% (N4859)
of the study population had a PDC80. The average total medical/pharmacy costs
were higher for the adherent patients, primarily due to their higher pharmacy
costs. Individuals who were adherent to their cardiovascular medications had
lower short-term disability costs ($1331/year) than did the non-adherent
($1828/year). CONCLUSIONS: In general, patients who were adherent to their sta-
tin/anti-hypertensive drug regimens had lower short-termdisability costs than did
the non-adherent. Employers concerned with the relationship between cardiovas-
cular disease and employee costs should also consider the effect of adherence to
statins and antihypertensives on short-term disability costs.
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OBJECTIVES: Describe health care utilization and costs associated with acromeg-
aly, a rare pituitary disorder that may result in considerable comorbidities and for
which data on US health care costs are limited. METHODS: Retrospective claims
study in a US commercial health plan analyzed adults with an acromegaly-related
diagnosis, procedure, or medication between July 2002 to June 2010. Subjects were
observed for sixmonths before their first acromegaly-related claim and until death
or disenrollment. RESULTS: A totlal of 1056 subjects had mean (SD) age of 42 (17.2)
years on their first acromegaly claim; 49% were male. Common comorbidities in-
cluded hypertension (23.2%), diabetes (14.4%), and arthropathy (14.3%). Most com-
mon specialty office visits included neurology (66.4%), endocrinology (58.2%), and
ophthalmology/optometry (45.8%). A majority of subjects (72.8%) visited a primary
care physician (PCP). Average number of office visits per-year was 4.8 for PCPs, 2.2
for endocrinologists, 1.5 for neurologists, and 0.6 for ophthalmologists/optome-
trists. Proportion with any all-cause and acromegaly-related healthcare utilization
included 99.9% and 96.7% with an ambulatory visit, respectively, 48.6% and 6.8%
with an emergency room visit, and 45.9% and 25.4% with an inpatient admission.
Total all-cause healthcare costs (medicalpharmacy) averaged $2255/per-mem-
ber-per-month. While pharmacy costs comprised 19.1% ($431/2255) of total costs,
ambulatory and inpatient costs comprised the highest proportion of total medical
costs, 48.1% ($877/1,825) and 44.7% ($815/1,825), respectively. Of total all-cause
health care costs, 44.6% was for total acromegaly-related care ($1,005/2,255). Of
total acromegaly-related medical costs, 63.3% ($498/787) was for acromegaly-re-
lated inpatient care. CONCLUSIONS: While acromegaly is generally under-diag-
nosed, subjects in this study had substantial health care utilization and costs for
acromegaly-related care. Subjects visited a PCP most often, suggesting that sub-
stantial diseasemanagementwas provided by physicianswhomay only treat a few
acromegaly patients during theirmedical careers. Future studies focusing on treat-
ment patterns prior to confirmed acromegaly diagnosis may increase awareness
and expedite diagnosis of this condition in an earlier stage.
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OBJECTIVES: To quantify the resource utilization predictors and cost of cardiovas-
cular disease using the Australian Reduction of Atherothrombosis for Continued
Health (REACH) registry. METHODS: This paper describes two-year cost data esti-
mated using a bottom-up costing approach, and presents patterns of resource
utilization based on types of vascular disease. Themultivariate predictors of num-
ber of hospitalization, medication and other health services used per patient and
related costs at two-year follow-upwere examinedusing generalized linearmodels
(GLM). Government reimbursement data from 2011 was used to calculate direct
health care costs. RESULTS: Overall 2873 of the total 68 236 patients in the REACH
registry cohort were enrolled from Australia. The two-year follow-up data was
available for 2856 (99.4%) patients with or at high risk of atherothrombosis. Overall,
the mean (SD) direct expenditure over 24 months of follow-up per person was
$7544 ($10 758). In the adjustedmodel, patients with coronary artery disease (CAD)
and peripheral arterial disease (PAD) incurred A$1255 (95% CI $199 to $2310) and
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